TCR² Raises $125M to Move Ahead with Its Cell Therapy, CAR-T’s Cousin – Xconomy
|
TCR² Raises $125M to Move Ahead with Its Cell Therapy, CAR–T’s Cousin
Xconomy TCR² Therapeutics has raised a $125 million Series B round to push ahead with live, cancer-fighting T cells. T cell receptor (TCR) therapies, the firm’s area of focus, have not progressed as far as higher-profile CAR-T treatments, despite similarities … |
Xconomy |
TCR² Raises $125M to Move Ahead with Its Cell Therapy, CAR–T’s Cousin
Xconomy TCR² Therapeutics has raised a $125 million Series B round to push ahead with live, cancer-fighting T cells. T cell receptor (TCR) therapies, the firm’s area of focus, have not progressed as far as higher-profile CAR-T treatments, despite similarities … |
Technology Networks |
Cell & Gene Therapy Manufacturing Digital Week
Technology Networks That’s right! KNECT365 Life Science is holding a week packed full of webinars! And what’s more, the content is completely free and will be accessible on demand. Cell & Gene Therapy Manufacturing Digital week-long series with live Q&A continues to … |
Technology Networks |
Cell & Gene Therapy Manufacturing Digital Week
Technology Networks That’s right! KNECT365 Life Science is holding a week packed full of webinars! And what’s more, the content is completely free and will be accessible on demand. Cell & Gene Therapy Manufacturing Digital week-long series with live Q&A continues to … |
STAT |
‘That’s $425000 right there’ — the anxious launch of a gene therapy with a record sticker price
STAT The treatment, developed after decades of research, is called Luxturna, and it is sometimes referred to as the first “true” gene therapy 6 to be approved by the Food and Drug Administration. Cancer treatments 7 such as Kymriah and Yescarta are also … |